Online inquiry

IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1233MR)

This product GTTS-WQ1233MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TPBG gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Non-small lung carcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001166392.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7162
UniProt ID Q13641
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1233MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2256MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ5462MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ8176MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ15844MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ8083MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ2268MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ10098MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ12674MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-18R5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW